explore -WSS

explore

author：leisure time 2025-08-12 08:28:36 - browse：679

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： 5 ways to address the shortage of health care workers

hotspot

WSS

Laying a path for careers in science

Pancreatic cancer is often deadly, but new discoveries are raising hope

Harvard scientists, with Google, unveil the most detailed brain map ever

Bird flu in dairy cattle: New measures to control spread to humans

Scientific mystery highlights the blind spots in genomics databases

Childhood vaccination ad campaign launches in the U.K.

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

New air purifier tech could be key to improving indoor air quality

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

United colonoscopy coverage change 'may cost lives,' doctors say

Trial using CRISPR to edit HIV out of cells disappoints

Malaria cases in Florida and Texas: Here’s what you need to know

NEJM study measures Covid brain fog, impact on IQ

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Oral obesity drug from Viking Therapeutics hits key early target

knowledge

Oral obesity drug from Viking Therapeutics hits key early target

Gut bacteria may contribute to kidney autoimmunity, study finds

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

UnitedHealth, in a surprise, takes aim at Steward’s physician group

STAT Madness 2024: Meet the contenders

Covid silver lining: Unprecedented look at human immune system

hotspot

leisure time

hotspot

focus